Children as young as six to be tested for Oxford/AstraZeneca vaccine efficacy

Trial will use 300 volunteers to assess whether jab produces strong immune response in children aged six to 17

• Coronavirus - latest updates
• See all our coronavirus coverage

The efficacy of the Oxford/AstraZeneca vaccine in children is due to be tested in a new clinical trial beginning this month.

Researchers will use 300 volunteers to assess whether the jab - known as the the ChAdOx1 nCoV-19 vaccine - produces a strong immune response in children aged between six and 17.